Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?

IF 3.1 4区医学 Q2 INFECTIOUS DISEASES

Current Infectious Disease Reports Pub Date : 2024-02-10 DOI:10.1007/s11908-024-00831-1

Blake R. Mangum, Jason M. Pogue, Katie E. Barber

{"title":"Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?","authors":"Blake R. Mangum, Jason M. Pogue, Katie E. Barber","doi":"10.1007/s11908-024-00831-1","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Infectious Disease Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11908-024-00831-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens.

Recent Findings

To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards.

Summary

Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.

查看原文本刊更多论文

替比培南和舒洛培南：活力二重奏还是双重麻烦？

综述目的抗菌药耐药性对公共卫生的威胁日益严重，在美国每年导致数百万人感染抗生素，数千人死亡。其中一个令人担忧的问题是产广谱β-内酰胺酶（ESBL）肠杆菌的增加。目前的治疗通常需要静脉注射碳青霉烯类药物，导致住院时间延长和经济负担加重。为了解决这一问题，目前正在研究新型口服培南制剂--替比培南和舒洛培南。它们以原药的形式给药，在胃肠道发挥活性之前提高了生物利用度，有可能治疗门诊环境中的耐多药感染。尽管在临床试验中前景看好，但仍存在一些挑战，如替比培南的肾排泄问题，需要针对肾功能障碍调整剂量。小结替比培南和舒洛培南为抗菌药耐药性（尤其是尿路感染）提供了潜在的口服解决方案，但最佳剂量和药敏试验仍需进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Infectious Disease Reports INFECTIOUS DISEASES-

CiteScore

6.70

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of infectious disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as HIV/AIDS, sexually transmitted diseases, tropical and travel medicine, and urinary tract infections. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists.